参考文献/References:
[1] Dey AK, Groenendyk J, Mehta NN, et al. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes[J]. Clin Cardiol, 2019,42(3):406-412.
[2] Forst T, Hanefeld M, Jacob S, et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies[J]. Diab Vasc Dis Res, 2013,10(4):302-314.
[3] Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications[J]. Kidney Int, 2009,75(12): 1272-1277.
[4] Gnudi L, Karalliedde J. Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents[J]. Nephrol Dial Transplant,2016,31(7): 1036-1043.
[5] Gupta P, White WB. Cardiovascular safety of therapies for type 2 diabetes[J]. Expert Opin Drug Saf, 2017,16(1):13-25.
[6] Vallon V,Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition[J]. Diabetologia, 2017, 60(2):215-225.
[7] Salsali A, Kim G, Woerle HJ, et al. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials[J]. Diabetes Obes Metab,2016,18(10):1034-1040.
[8] Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017,377(7):644-657.
[9] Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019,380(4):347-357.
[10] Herrington WG, Preiss D, Haynes R, et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study[J]. Clin Kidney J, 2018,11(6):749-761.
[11] MacIsaac RJ, Jerums G, Ekinci EI. Cardio-renal protection with empagliflozin[J]. Ann Transl Med, 2016,4(20):409.
[12] Borghetti G, von Lewinski D, Eaton DM, et al. Diabetic cardiomyopathy: current and future therapies. beyond glycemic control[J]. Front Physiol, 2018,9: 1514.
[13] Lahnwong S,Chattipakorn SC, Chattipakorn N. Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors[J]. Cardiovasc Diabetol, 2018,17(1):101.
[14] Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume[J]. Cardiovasc Diabetol, 2018,17(1):6.
[15] Zinman B, Wanner C, Lachin J M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015,373(22): 2117-2128.
[16] Kosiborod M,Cavender MA,Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)[J]. Circulation, 2017,136(3):249-259.
[17] 吴兵书. SGLT-2抑制剂联合胰岛素治疗糖尿病对心血管疾病危险因素的影响—一项随机对照试验的荟萃分析[D]. 沈阳:中国医科大学, 2018.
[18] 孙芳. 高盐摄入通过SGLT2调控血糖稳态的机制[D]. 重庆:第三军医大学, 2017.
[19] Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2015,17(12):1180-1193.
[20] Wong DT,Puri R,Richardson JD,et al. Myocardial ’no-reflow’--diagnosis, pathophysiology and treatment[J]. Int J Cardiol, 2013,167(5):1798-1806.
[21] Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind,placebo-controlled,phase 3 trial[J]. Diabetes Care,2010,33(10): 2217-2224.
[22] Matthaei S, Bowering K, Rohwedder K, et al. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial[J]. Diabetes Care, 2015,38(3): 365-372.
[23] Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study[J]. Diabetes Care, 2015,38(3):355-364.
[24] Wu AH, Gladden JD, Ahmed M, et al. Relation of serum uric acid to cardiovascular disease[J]. Int J Cardiol, 2016,213:4-7.
[25] Davies MJ, Trujillo A, Vijapurkar U, et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab, 2015, 17(4): 426-429.
[26] Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors[J]. Diabetes Obes Metab, 2019,21(6):1291-1298.
[27] Pleros C, Stamataki E, Papadaki A, et al. Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report[J]. CEN Case Rep, 2018,7(1):17-20.
[28] Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2016,101(1):157-166.
[29] Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin [J]. J Clin Endocrinol Metab, 2016,101(1):44-51.
[30] Ruanpeng D, Ungprasert P, Sangtian J, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus:a meta-analysis[J]. Diabetes Metab Res Rev, 2017,33(6):e2903.
[31] Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines[J]. Circulation, 2019,140(11):e596-e646.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(9):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(9):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(9):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(9):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(9):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]